Every 424B that IperionX Limited (IPX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IPX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IPX filings page.
IperionX Limited is conducting a firm commitment public offering of 2,275,000 ADSs, each ADS representing ten ordinary shares, at a public offering price of $21.98 per ADS. The offering is being sold by the company and is expected to deliver proceeds to the issuer.
Net proceeds are estimated at approximately $46.0 million after underwriting discounts, commissions and estimated offering expenses. The ADSs are listed on Nasdaq under the symbol IPX. Ordinary shares outstanding immediately after this offering are stated as 359,072,679 ordinary shares.
IperionX Limited proposes a firm commitment public offering of American Depositary Shares (ADSs), each representing 10 ordinary shares, to raise capital to advance commercialization and scale-up of its titanium production technologies and to support the Titan-Camden critical minerals development.
Recent operational and financing context disclosed includes HAMR™ powder production of approximately 4.2 metric tons in March 2026 (about 50 metric tons per year annualized), a US$47.1 million Industrial Base Analysis and Sustainment award supporting a 1,400 metric tons per year expansion program, receipt of approximately 290 metric tons of titanium scrap from the U.S. Government, and US$48.2 million in cash as of March 31, 2026. The prospectus supplement describes use of proceeds for Virginia manufacturing scale-up, Titan-Camden activities and general corporate purposes.
IperionX Limited is offering 1,273,179 ordinary shares pursuant to a prospectus supplement dated February 23, 2026, with an offering price of $4.11 per share under a settlement agreement. The company will receive no proceeds from this issuance.
The shares are being sold directly by the company without underwriters and are expected to settle on or prior to February 24, 2026. Ordinary shares to be outstanding immediately after this offering are stated as 339,384,070 ordinary shares.